Multiple effectiveness aspects of tapentadol for moderate–severe cancer-pain treatment: an observational prospective study

References

• van den Beuken-van EverdingenMHHochstenbachLMJoostenEATjan-HeijnenVCJanssenDJUpdate on prevalence of pain in patients with cancer: systematic review and meta-analysisJ Pain Symptom Manage20165161070109027112310
   PubMed Web of Science ®Google Scholar
• van LeeuwenMHussonOAlbertiPUnderstanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaireHealth Qual Life Outcomes201816111429866185
   PubMed Web of Science ®Google Scholar
• Te BoveldtNVernooij-DassenMBurgerNIjsseldijkMVissersKEngelsYPain and its interference with daily activities in medical oncology outpatientsPain Physician201316437938923877454
   PubMed Web of Science ®Google Scholar
• ZechDFGrondSLynchJHertelDLehmannKAValidation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective studyPain199563165768577492
   PubMed Web of Science ®Google Scholar
• RipamontiCISantiniDMaranzanoEBertiMRoilaFESMO Guidelines Working GroupManagement of cancer pain: ESMO Clinical Practice GuidelinesAnn Oncol201223Suppl 7vii13915422997447
   PubMed Web of Science ®Google Scholar
• CaraceniAHanksGKaasaSUse of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol2012132e58e6822300860
   PubMed Web of Science ®Google Scholar
• ChouRTurnerJADevineEBThe effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention WorkshopAnn Intern Med2015162427628625581257
   PubMed Web of Science ®Google Scholar
• BenyaminRTrescotAMDattaSOpioid complications and side effectsPain Physician2008112 SupplS105S12018443635
   PubMed Web of Science ®Google Scholar
• TzschentkeTMChristophTKögelB(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther2007323126527617656655
   PubMed Web of Science ®Google Scholar
• KressHGTapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?Eur J Pain201014878178320659810
   PubMed Web of Science ®Google Scholar
• MengZYuJAcuffMTolerability of opioid analgesia for chronic pain: a network meta-analysisSci Rep201771199528515426
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFerreraPTapentadol in cancer pain management: a prospective open-label studyCurr Med Res Opin201228111775177923057488
   PubMed Web of Science ®Google Scholar
• KressHGKochEDKosturskiHTapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related painPain Physician201417432934325054392
   PubMed Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMEfficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related painCurr Med Res Opin201329101399140923937387
   PubMed Web of Science ®Google Scholar
• ImanakaKTominagaYEtropolskiMOhashiHHiroseKMatsumuraTReady conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseClin Drug Investig2014347501511
   PubMed Web of Science ®Google Scholar
• SchikowskiAKringsDSchwenkeKTapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patientsJ Pain Res201581825565884
   PubMed Web of Science ®Google Scholar
• WiffenPJDerrySNaessensKBellRFOral tapentadol for cancer painCochrane Database Syst Rev201599CD011460
   Google Scholar
• MercadanteSPorzioGAdileCTapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer painCurr Med Res Opin201430102063206824926734
   PubMed Web of Science ®Google Scholar
• Carmona-BayonasAJiménez FonsecaPVirizuela EchaburuJTapentadol for cancer pain management: a narrative reviewPain Pract20171781075108828084045
   PubMed Web of Science ®Google Scholar
• GRÜNENTHAL ITALIAPalexia. Foglio Illustrativo: Informazioni Per L’utilizzatore Available from: https://farmaci.agenzia-farmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_040423_FI.pdf&retry=0&sys=m0b1l3Accessed July 14, 2018
   Google Scholar
• MercadanteSPorzioGAielliFOpioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioidsCurr Med Res Opin201329666166623540512
   PubMed Web of Science ®Google Scholar
• OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496567165009
   PubMed Web of Science ®Google Scholar
• BouhassiraDAttalNAlchaarHComparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)Pain20051141–2293615733628
   PubMed Web of Science ®Google Scholar
• MercadanteSDardanoniGSalvaggioLArmataMGAgnelloAMonitoring of opioid therapy in advanced cancer pain patientsJ Pain Symptom Manage19971342042129136231
   PubMed Web of Science ®Google Scholar
• Addington-HallJMMacDonaldLDAndersonHRCan the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care?Br J Cancer19906246956992223593
   PubMed Web of Science ®Google Scholar
• BennettMIRaymentCHjermstadMAassNCaraceniAKaasaSPrevalence and aetiology of neuropathic pain in cancer patients: a systematic reviewPain2012153235936522115921
   PubMed Web of Science ®Google Scholar
• SugiyamaYKataokaTTasakiYEfficacy of tapentadol for first-line opioid-resistant neuropathic pain in JapanJpn J Clin Oncol201848436236629506199
   PubMed Web of Science ®Google Scholar
• FalkSPatelRHeegaardAMercadanteSDickensonAHSpinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approachEur J Pain201519215215824917026
   PubMed Web of Science ®Google Scholar
• OnoHNakamuraAKanbaraTEffect of the norepinephrine transporter (NET) inhibition on µ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain modelJ Pharmacol Sci2014125326427324965165
   PubMed Web of Science ®Google Scholar
• MercadanteSBrueraEOpioid switching: a systematic and critical reviewCancer Treat Rev200632430431516624490
   PubMed Web of Science ®Google Scholar
• CascellaMCuomoAViscardiDPharmacological approachesCascellaMCuomoAViscardiDFeatures and Management of the Pelvic Cancer PainVerlagSpringer20167393
   Google Scholar